<DOC>
	<DOCNO>NCT00401076</DOCNO>
	<brief_summary>This study evaluate safety 3.0 g/day SA-001 ( flexibly increase decrease range 1.5 g/day 6.0 g/day ) , orally administer 52 week patient pancreatic exocrine insufficiency cause chronic pancreatitis non-compensatory stage pancreatectomy .</brief_summary>
	<brief_title>A Open-label Study Assess Safety Oral Long-term Use SA-001 Pancreatic Exocrine Insufficiency</brief_title>
	<detailed_description />
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Pancreatitis , Chronic</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<criteria>Inclusion Criteria Subjects complete S245.3.122 clinical study ( exclude discontinue subject ) . Exclusion Criteria Subjects assess inappropriate continue longterm use SA001 , discretion investigator subinvestigator , experienced adverse drug reaction S245.3.122 clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>SA-001</keyword>
	<keyword>Pancreatic Exocrine Insufficiency</keyword>
	<keyword>Chronic Pancreatitis</keyword>
	<keyword>Pancreatectomy</keyword>
</DOC>